JP Morgan Chase
TGTX icon

JP Morgan Chase’s TG Therapeutics TGTX Stock Holding History

JP Morgan Chase’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,000
Closed -$864K – 7723
2025
Q2 		$864K Hold
24,000
– – ﹤0.01% 4471
2025
Q1 		$946K Hold
24,000
– – ﹤0.01% 4391
2024
Q4 		$722K Buy
+24,000
New +$689K ﹤0.01% 4840
2021
Q4 		– Sell
-375,000
Closed -$12.5M – 6952
2021
Q3 		$12.5M Hold
375,000
– – ﹤0.01% 2193
2021
Q2 		$14.5M Buy
+375,000
New +$14.7M ﹤0.01% 2102
2019
Q2 		– Sell
-185,700
Closed -$1.49M – 6012
2019
Q1 		$1.49M Buy
+185,700
New +$1M ﹤0.01% 3534

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase's TGTX Position: Q1 2026 in Review

JP Morgan Chase increased its TG Therapeutics (TGTX) stake by 14% in Q1 2026, buying an estimated $554K and bringing the position to 150,523 shares worth $4.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3360.

JP Morgan Chase first reported a position in TGTX in Q2 2013 and has held it in 45 quarters since. The position peaked at $23.2M in Q1 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • JP Morgan Chase held 150,523 shares of TG Therapeutics worth $4.74M as of Q1 2026.
  • JP Morgan Chase bought 18,577 TG Therapeutics shares in Q1 2026, an estimated $554K.
  • TG Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3360 holding.
  • JP Morgan Chase first reported a position in TG Therapeutics in Q2 2013 and has held it in 45 quarters since.
  • JP Morgan Chase's TG Therapeutics position peaked at $23.2M in Q1 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.